Patients with myasthenia gravis may be unable to access new therapies for the condition because Australia’s PBS reimbursement system makes it difficult to list treatments for rare diseases, industry experts have told a Parliamentary inquiry. Treatments such as rozanolixizumab and zilucoplan are now in late-stage trials for the treatment of myasthenia gravis but manufacturers say ...
Myasthenia gravis therapies face reimbursement barriers: inquiry
By Michael Woodhead
10 May 2021